Adagio Medical Holdings, Inc.
No enriched coverage for $ADGM in the last 7 days.
No SEC Form 4 filings for $ADGM in the last 30 days.
See all $ADGM insider activity →Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for th
Adagio Medical (ADGM) shares rose 21.6% Monday and jumped 22% after hours, after the company said its next-generation vCLAS Ultra ULTA system treated its first patient at the University of Pennsylvania. Adagio also said the FDA approved expanding its FULCRUM-VT IDE trial for the new system and expects first-generation ULTA FDA approval soon.
Adagio Medical Holdings (ADGM) said it treated its first patient with its next-generation vCLAS Ultra ultra-low temperature ablation system under FDA expanded access. The patient with non-ischemic cardiomyopathy and prior failed VT ablations was treated at the University of Pennsylvania. Adagio also noted IDE approval for its FULCRUM-VT trial and reported no VT recurrence two months later.
Recent ADGM coverage spans technology, financial news and regulation.
The filing combines financials with fresh FDA-facing milestones, which can re-rate near-term approval and funding expectations for ADGM.
The FDA IDE expansion plus early first-patient outcome narrative can re-rate perceived clinical and regulatory progress for ADGM’s next-gen ablation platform.
First-in-human milestone plus FDA authorization for the FULCRUM-VT IDE trial supports the ULTA platform narrative and can drive near-term momentum.
First-in-human Expanded Access success plus FDA IDE expansion for the next-gen system increases near-term clinical/regulatory momentum for ADGM’s ULTA platform.
First-in-human treatment plus performance claims can re-rate perceived clinical readiness and near-term trial momentum for vCLAS Ultra.
alphai scores every news story that mentions ADGM with an AI model for sentiment and relevance, and aggregates insider trades from Adagio Medical Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for th
6 min readAdagio Medical (ADGM) shares rose 21.6% Monday and jumped 22% after hours, after the company said its next-generation vCLAS Ultra ULTA system treated its first patient at the University of Pennsylvania. Adagio also said the FDA approved expanding its FULCRUM-VT IDE trial for the new system and expects first-generation ULTA FDA approval soon.
5 min readAdagio Medical Holdings (ADGM) said it treated its first patient with its next-generation vCLAS Ultra ultra-low temperature ablation system under FDA expanded access. The patient with non-ischemic cardiomyopathy and prior failed VT ablations was treated at the University of Pennsylvania. Adagio also noted IDE approval for its FULCRUM-VT trial and reported no VT recurrence two months later.
3 min readAdagio Medical Holdings (Nasdaq: ADGM) said the FDA granted Expanded Access authorization for its next-generation vCLAS Ultra ULTA system, and clinicians at the Hospital of the University of Pennsylvania treated the first patient with ventricular tachycardia after prior failed ablations. The company expects IDE expansion of its FULCRUM-VT trial to assess the system for sustained monomorphic VT.
4 min readAdagio Medical Holdings Inc. said it treated the first patient with its next-generation vCLAS Ultra low-temperature ablation system. The company claims it can reach -170°C and cut ablation time by 50% to 75%, shortening procedures by up to 30 minutes versus the prior system. Adagio noted the FDA granted IDE approval in April to expand its FULCRUM-VT trial. Shares rose 19% to 45 cents.
3 min readAdagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0002006986 0002006986 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readAdagio Medical Holdings submitted a premarket approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System to treat ventricular tachycardia. The filing is supported by six-month Fulcrum-VT IDE trial data: 84% avoided device shocks and 59% had no VT recurrence. Adagio said the system has CE Mark approval; shares trade near $0.75.
6 min readAdagio Medical has submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, designed to treat drug-refractory, recurrent ventricular tachycardia. This submission is supported by positive data from the FULCRUM-VT pivotal trial, which showed high acute clinical success and significant improvements in patient outcomes. The company believes this endocardial-only approach could democratize VT ablation and address a major unmet need in treating both ischemic and non-ischemic cardiomyopathy.
3 min readAdagio Medical Holdings, Inc. (NASDAQ: ADGM) released its Q1 2026 unaudited financial results, reporting no revenue and a net loss per share of $0.31. The company remains in a critical pre-commercialization phase, relying on external capital with $17.1 million in cash and $22.87 million in convertible notes. Investors face risks including potential dilution from capital raises and convertible debt, and the ongoing need for funding before commercialization.
3 min readThis page provides live quotes and charts for Adagio Medical Holdings Inc (ADGM) stock on NASDAQ, showing a current price of $0.9750 with a 2.31% gain. It also notes that there is no analyst rating information or earnings data currently available for the company. The page is primarily a portal offering tools, guides, and educational content related to stock trading from StocksToTrade.com.
2 min read
